Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALPS Plus: 5% Albumin vs 20% Albumin + Plasmalyte in Cirrhosis
NCT06076330Phase 3Unknown
- Sponsor
- Institute of Liver and Biliary Sciences
- Start
- Sep 2023
- Primary completion
- Aug 2024
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of albumin (human), plasmalyte in septic shock, sponsored by Institute of Liver and Biliary Sciences. Status: unknown.
02
Drugs
albumin (human)plasmalyte
03
Conditions
septic shock
Beyond the preview
Go deeper on NCT06076330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06076330.